Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IDEAYA Biosciences (IDYA) EBITDA (2020 - 2025)

Historic EBITDA for IDEAYA Biosciences (IDYA) over the last 6 years, with Q4 2025 value amounting to -$83.1 million.

  • IDEAYA Biosciences' EBITDA rose 3770.77% to -$83.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$143.2 million, marking a year-over-year increase of 4778.49%. This contributed to the annual value of -$112.2 million for FY2025, which is 5906.93% up from last year.
  • Latest data reveals that IDEAYA Biosciences reported EBITDA of -$83.1 million as of Q4 2025, which was up 3770.77% from $119.8 million recorded in Q3 2025.
  • In the past 5 years, IDEAYA Biosciences' EBITDA ranged from a high of $119.8 million in Q3 2025 and a low of -$133.3 million during Q4 2024
  • Moreover, its 5-year median value for EBITDA was -$23.0 million (2022), whereas its average is -$25.5 million.
  • As far as peak fluctuations go, IDEAYA Biosciences' EBITDA tumbled by 227479.87% in 2023, and later surged by 35719.9% in 2025.
  • IDEAYA Biosciences' EBITDA (Quarter) stood at -$18.9 million in 2021, then decreased by 22.23% to -$23.1 million in 2022, then plummeted by 41.5% to -$32.6 million in 2023, then plummeted by 308.47% to -$133.3 million in 2024, then soared by 37.71% to -$83.1 million in 2025.
  • Its EBITDA stands at -$83.1 million for Q4 2025, versus $119.8 million for Q3 2025 and -$133.3 million for Q4 2024.